iSpecimen (ISPC) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MaxCyte is the larger company by market cap ($107.3 million vs $2.8 million), about 38.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ISPC | MXCT |
|---|---|---|
| Share price | $1.10 | $1.04 |
| Market cap | $2.77M | $107.33M |
| 1-day change | +2.80% | -4.59% |
| YTD return | — | -32.90% |
| 1-year return | — | -32.90% |
| 5-year return | — | -90.57% |
| EPS (TTM) | $-52.98 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.04 | $1.87 |
| 52-week low | $1.02 | $0.643 |
| Distance from 52-week high | -97.25% | -44.24% |
| Average volume | 671.33K | 685.34K |
| Shares outstanding | 2.52M | 103.21M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MaxCyte is about 38.7 times larger than iSpecimen by market value ($107.33M vs $2.77M).
ISPC vs MXCT FAQ
Which is bigger, iSpecimen or MaxCyte?
MaxCyte (MXCT) is larger, with a market capitalization of $107.33M compared with $2.77M for iSpecimen (ISPC).
Are iSpecimen and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.